

Anti-cancer drug induced peripheral neuropathy (AIPN) screening tool

Early detection and intervention are important in managing symptoms of AIPN and preventing the development of more severe neuropathy. It is recommended that assessment is undertaken by the patient or health care professional with each dose of drug. It is important to be aware of a patient's pre-existing conditions involving neurological damage, as this increases the risk of AIPN.

Hospital ID: _____ MRN: _____

Surname: _____

Given names: _____

Date of birth: _____ Sex: _____ AMO: _____

Pronouns: _____

Preferred names: _____

Treatment protocol: _____ Date: _____ Cycle: _____ Day: _____

Neuropathy screening	Yes	No
----------------------	-----	----

History of neuropathy?		
------------------------	--	--

Details:

Pre-existing conditions that may contribute to neuropathy (e.g. diabetes, nutritional deficiencies –vitamin b12 & thiamine, alcohol abuse, Lyme disease, lupus, infiltrating tumours or spinal cord compression, previous radiation therapy)

Details:

Assess the patient for signs and symptom of peripheral neuropathy within the past 7 days and grade the following according to the CTCAE grading: 0 – nil, 1 – mild, 2 – moderate, 3 – severe, 4 – life-threatening.

Date							
Cycle/day							
Signs							
Numbness or tingling in hands or feet							
Discomfort, burning or shooting pain to hands or arms							
Discomfort, burning or shooting pain to feet or legs							
Difficulty distinguishing between the feeling of hot and cold in hands or feet							
Muscle cramps or spasms to hands or arms							
Muscle cramps or spasms to feet or legs							
Weakness to hands or arms							
Weakness to feet or legs							
Difficulty standing or walking							
Recent fall/s within the past 7 days							
Difficulty undertaking activities of daily living (ADLs) with hands e.g. writing, holding a pen or small items, doing up buttons.							
Constipation							
Hearing loss, ringing or buzzing in ears							
Dizziness							
Assessor signature:							

Where toxicity is suspected, medical review should be organised and appropriate escalation procedures undertaken as per local policy

Date	Comments/Action	Initials

E: feedback@eviq.org.au
W: eviq.org.au

© Cancer Institute NSW. Version 5. Last reviewed July 2023. This document reflects what is currently regarded as safe practice. While every effort has been made to ensure the accuracy of the contents at the time of publication, the Cancer Institute NSW does not accept any liability, with respect to loss, damage, injury, or expense arising from any such errors or omission in the contents of this work. Any reference throughout the document to specific pharmaceuticals and/or medical products as examples does not imply endorsement of any of these products. See www.eviq.org.au for our full disclaimer and any updates.

